Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs JPMorgan Chase & Co — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $69 (market cap $30.93B), while JPMorgan Chase & Co trades at $338.61 (market cap $890.37B). The key difference: JPMorgan Chase & Co is far larger — about 28.8× GE HealthCare Technologies Inc. Common Stock's market cap, and JPMorgan Chase & Co pays the higher dividend (1.97%). Which is the better fit depends on your goals.
| GEHC | JPM | |
|---|---|---|
Market Cap | $30.93B | $890.37B |
Volume | 5,033,451 | 10,236,412 |
Sector | Health | Financials |
52-Week High | $88.16 | $365.18 |
52-Week Low | $59.48 | $282.84 |
Enterprise Value | $39.39B | $1.40T |
Dividend Yield | 0.23% | 1.97% |
Typical Hold Time | — | 127 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
JPMorgan Chase (JPM) trades at $331.43, down 0.86% on the day, with a bearish technical signal despite strong fundamentals. The company reported mixed Q3 2026 earnings but beat expectations in Q1 and Q2, with revenue growing to $181.85B in 2025. Analyst consensus remains positive with a $373.36 price target, though technical indicators show resistance near $336-339 levels.
JPMorgan offers solid investment potential with strong profitability (33.38% net margin) and attractive valuation (P/E 13.9), but faces headwinds from negative cash flow trends and geopolitical risks highlighted in recent CEO warnings. The stock's current technical weakness suggests near-term consolidation before potential upside toward analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
